Open Access<p>Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis</p>
Author(s) -
Vidhatha Reddy,
Eric J. Yang,
Bridget Myers,
Wilson Liao
Publication year - 2020
Publication title -
journal of inflammation research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.656
H-Index - 33
ISSN - 1178-7031
DOI - 10.2147/jir.s215196
Subject(s) - medicine , psoriasis , plaque psoriasis , dosing , clinical trial , pharmacodynamics , pharmacokinetics , interleukin 23 , psoriasis area and severity index , pharmacology , dermatology , interleukin 17 , inflammation
Risankizumab-rzaa (Skyrizi ® ; AbbVie) is a humanized IgG monoclonal antibody directed against interleukin-23p19 (IL-23p19) indicated for the treatment of moderate-to-severe psoriasis in adults who are candidates for systemic therapy or phototherapy. Four pivotal Phase III trials: UltIMMa-1, UltIMMa-2, IMMhance, and IMMvent have demonstrated efficacy and safety in patients with moderate-to-severe plaque psoriasis. This review highlights important findings from these and other clinical trials that have evaluated risankizumab. In addition, we discuss the mechanism of action, pharmacokinetics/pharmacodynamics, dosing recommendations, drug interactions, other potential indications, and ongoing clinical trials.